drugset / Trial / NCT06732245
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
RandomizedFactorialDouble-blindTreatment
Summary
A phase 2 study to assess the efficacy of NA-931 alone or in addition to Tirzepatide to assess efficacy and safety in overweight or obese men and women
Timeline
- Start
- 2026-08-15
- Primary completion
- 2027-08-15
- Completion
- 2027-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | NA-931 | Peptide | 60 mg | Oral |
| Comparator | NA-931 | Peptide | 120 mg | Oral |
| Comparator | NA-931 | Peptide | 150 mg | Oral |
| Comparator | Tirzepatide | Peptide | 2.5 mg | Subcutaneous |
| Comparator | Tirzepatide | Peptide | 5 mg | Subcutaneous |
| Comparator | Tirzepatide | Peptide | 10 mg | Subcutaneous |